Clinical trials
Neoplasms trials in Lithuania
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2011 | 2 |
| 2012 | 3 |
| 2014 | 1 |
| 2017 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Recruiting | 6 |
| Active, not recruiting | 3 |
| Terminated | 3 |
| Unknown status | 3 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen | 2 |
| Lithuanian University of Health Sciences | 2 |
| AbbVie | 1 |
| Astellas Pharma Global Development, Inc. | 1 |
| Bayer | 1 |
| BioNumerik Pharmaceuticals, Inc. | 1 |
| Cantargia AB | 1 |
| Egalet Ltd | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 24 |
| Neoplasm Metastasis | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Colorectal Neoplasms | 2 |
| Lung Neoplasms | 2 |
| Multiple Myeloma | 2 |
| Recurrence | 2 |
| Adenocarcinoma | 1 |
| Blood Protein Disorders | 1 |
| Bone Diseases | 1 |
Trials
Showing 26 to 24 of 24. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.